Edition:
United States

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

7.60USD
23 Feb 2018
Change (% chg)

$0.10 (+1.33%)
Prev Close
$7.50
Open
$7.60
Day's High
$7.65
Day's Low
$7.45
Volume
9,415
Avg. Vol
21,498
52-wk High
$11.90
52-wk Low
$3.80

Select another date:

Tue, Jan 30 2018

BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Dry Eye Disease Phase 2B Clinical Trial

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN DRY EYE DISEASE PHASE 2B CLINICAL TRIAL Source text for Eikon: Further company coverage:

BRIEF-Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data

* ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Aldeyra Therapeutics reports Q3 loss per share of $0.32

* Aldeyra Therapeutics announces third quarter 2017 financial results

BRIEF-Aldeyra ‍announcesd new data for ADX-102 from Phase 2 clinical trials

* Aldeyra - ‍announced new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis​

BRIEF-Perceptive Advisors buys 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19

* Perceptive Advisors Llc reports purchase of 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19 at $7.25 per share - SEC filing

BRIEF-Aldeyra Therapeutics posts pricing of public offering of common stock

* Aldeyra Therapeutics Inc announces pricing of public offering of common stock

BRIEF-Aldeyra Therapeutics announces proposed public offering of common stock

* Aldeyra Therapeutics Inc announces proposed public offering of common stock

BRIEF-Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial

* Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial Source text for Eikon: Further company coverage:

Select another date: